Evidence map›Paper›PMID 21830069›Full record

ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2011

Cannabinoid neuroimmune modulation of SIV disease.

Patricia E Molina, Angela Amedee, Nicole J LeCapitaine, Jovanny Zabaleta, Mahesh Mohan, Peter Winsauer, Curtis Vande Stouwe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The impact of cannabinoids on inflammasome signaling in HIV-1 infection.NeuroImmune pharmacology and therapeutics · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. The Epigenetics of the Endocannabinoid System.International journal of molecular sciences · 2020
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Patricia E MolinaDepartment of Physiology, LSUHSC at New Orleans, 1901 Perdido Street, Medical Education Building, New Orleans, LA 70112, USA. pmolin@lsuhsc.edu
Angela Amedee
Nicole J LeCapitaine
Jovanny Zabaleta
Mahesh Mohan
Peter Winsauer
Curtis Vande Stouwe
Louisiana State University Health Sciences Center New Orleans · USTulane University · US

Funding

Cannabinoid Epigenomic and miRNA mechanisms impact HIV/SIV disease progressionR01DA030053 · NIDA · LSU HEALTH SCIENCES CENTER · PI MOLINA, PATRICIA E. · 2010 to 2014
$3.8M
Cannabinoid effects on HIV/AIDSR01DA020419 · NIDA · LSU HEALTH SCIENCES CENTER · PI MOLINA, PATRICIA E. · 2006 to 2010
$3.3M
Intramural NIH HHSNIDA NIH HHS R01 DA020419NIDA NIH HHS R01 DA030053
6 · The paper itself

Abstract

Marijuana is one of the most commonly used and abused drugs. Δ-9-tetrahydrocannabinol (Δ-9-THC), the primary psychoactive component in marijuana, is FDA-approved to ameliorate AIDS-associated wasting. Because cannabinoid receptors are expressed on cells of the immune system, it is possible that chronic Δ-9-THC use may impact HIV disease progression. Until recently, longitudinal, controlled, systems-approach studies on the effects of cannabinoids on disease progression were lacking. Data from our controlled studies in non-human primates show chronic Δ-9-THC administration prior to and during simian immunodeficiency virus (SIV) infection ameliorates disease progression, attenuates viral load and tissue inflammation, significantly reducing morbidity and mortality of SIV-infected macaques. Identification of possible mechanisms responsible for this modulation of disease progression is complicated due to the multiplicity of cannabinoid-mediated effects, tissue-specific responses to the viral infection, multiple cellular mechanisms involved in inflammatory responses, coordinated neuroendocrine and localized responses to infection, and kinetics of viral replication. Emerging results from our studies reveal that the overall mechanisms mediating the protective effects of cannabinoids involve novel epigenomic regulatory mechanisms in need of systematic investigation. Here, we review the evidence supporting an immunomodulatory role for cannabinoids and its impact on disease progression with focus on HIV/SIV infection.

Indexed as

AnimalsCannabinoidsHIV-1HIV InfectionsHumansNeuroimmunomodulationSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadCannabinoids

Identifiers

PMID21830069
PMCPMC3208744
OpenAlexW2031374798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.